CHA ÀÇ°úÇдëÇб³ Â÷º´¿ø professor

±³¼ö´Ô»çÁø
  • ½É¼º½Å
  • »êºÎÀΰú ±³¼ö
  • ¼Ò ¼Ó: °­³²Â÷º´¿ø
  • Àü¹®ºÐ¾ß : ÁÖ»ê±âÇÐ, °íÀ§ÇèÀÓ½Å, ºÎÀΰúÇÐ
  • Á÷ À§:
  • ¸Þ ÀÏ: ºñ°ø°³
  • Àü È­: 02.3468.3000
  • ÆÑ ½º: 02.558.1119
  • ÁÖ ¼Ò: ¼­¿ï½Ã °­³²±¸ ¿ª»ï1µ¿ 650-9
  • ȨÆäÀÌÁö:
  • ·Î±×ÀÎ

ÅǸ޴º

ÁÖ¿ä¹ßÇ¥³í¹®

ÁÖ¿ä¹ßÇ¥³í¹®
¹øÈ£ ±¸ºÐ Á¦¸ñ
20 (±¹¿Ü)SCIE Real-World Experience with Pembrolizumab Treatment in Patients with Heavily Treated Recurrent Gynecologic Malignancies
19 (±¹¿Ü)SCIE Real-World Experience with Pembrolizumab Treatment in Patients with Heavily Treated Recurrent Gynecologic Malignancies
18 (±¹¿Ü)SCIE Real-World Experience with Pembrolizumab Treatment in Patients with Heavily Treated Recurrent Gynecologic Malignancies
17 (±¹¿Ü)SCIE Real-World Experience with Pembrolizumab Treatment in Patients with Heavily Treated Recurrent Gynecologic Malignancies
16 (±¹¿Ü)SCIE Real-World Experience with Pembrolizumab Treatment in Patients with Heavily Treated Recurrent Gynecologic Malignancies
15 (±¹¿Ü)SCIE Real-World Experience with Pembrolizumab Treatment in Patients with Heavily Treated Recurrent Gynecologic Malignancies
14 (±¹¿Ü)SCI Atypical endometriosis is related to a higher recurrence rate
13 (±¹¿Ü)SCI Atypical endometriosis is related to a higher recurrence rate
12 (±¹¿Ü)SCI Atypical endometriosis is related to a higher recurrence rate
11 (±¹¿Ü)SCI Atypical endometriosis is related to a higher recurrence rate
ÀÌÀüÆäÀÌÁö À̵¿ 21 22 23 24 25 26 ´ÙÀ½ÆäÀÌÁö À̵¿
Copyright ¨Ï chamc, All rights reserved.

ºü¸£°í Æí¸®ÇÑ ÀÎÅÍ³Ý Áø·á¿¹¾à

  • °­³²Â÷º´¿ø
  • ºÐ´çÂ÷º´¿ø
  • ºÐ´çÂ÷¿©¼ºº´¿ø
  • ±¸¹ÌÂ÷º´¿ø
  • ¿©¼ºÀÇÇבּ¸¼Ò
  • Â÷¿ò

ÀüÈ­¹®ÀÇ

  • °­³²Â÷º´¿ø 02.3468.3000
  • ºÐ´çÂ÷º´¿ø 031.780.5000
  • Â÷¿ò 02.3015.5300
  • ±¸¹ÌÂ÷º´¿ø 054.450.9700
  • ´ë±¸¿©¼ºÂ÷º´¿ø 02.222.4200
  • °­³²°ÇÁø¼¾ÅÍ 02.2191.3900
  • ºÐ´çÁ¾ÇÕ°Ç°­ÁõÁø¼¾ÅÍ 031.780.5940
  • ½ºÆ÷·º½º °ÇÁø¼¾ÅÍ 02.3473.2111
  • ±¸¹ÌÂ÷º´¿ø°ÇÁø¼¾ÅÍ 054.450.9800
  • ȨÆäÀÌÁö°ü¸®ÀÚ 031.780.1729